NLS Pharmaceutics (NLSP) Competitors $2.51 -0.10 (-3.83%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.58 +0.07 (+2.59%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. JATT, MIRA, BDRX, NNVC, TENX, QTTB, CASI, RLYB, LGVN, and AYTUShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include JATT Acquisition (JATT), MIRA Pharmaceuticals (MIRA), Biodexa Pharmaceuticals (BDRX), NanoViricides (NNVC), Tenax Therapeutics (TENX), Q32 Bio (QTTB), CASI Pharmaceuticals (CASI), Rallybio (RLYB), Longeveron (LGVN), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors JATT Acquisition MIRA Pharmaceuticals Biodexa Pharmaceuticals NanoViricides Tenax Therapeutics Q32 Bio CASI Pharmaceuticals Rallybio Longeveron Aytu BioPharma JATT Acquisition (NYSE:JATT) and NLS Pharmaceutics (NASDAQ:NLSP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings. Is JATT or NLSP more profitable? NLS Pharmaceutics' return on equity of 0.00% beat JATT Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% NLS Pharmaceutics N/A N/A N/A Which has better earnings & valuation, JATT or NLSP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/ANLS PharmaceuticsN/AN/A-$1.98MN/AN/A Do institutionals and insiders believe in JATT or NLSP? 48.0% of JATT Acquisition shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 16.4% of NLS Pharmaceutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer JATT or NLSP? In the previous week, NLS Pharmaceutics had 4 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for NLS Pharmaceutics and 0 mentions for JATT Acquisition. NLS Pharmaceutics' average media sentiment score of 0.96 beat JATT Acquisition's score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the news media. Company Overall Sentiment JATT Acquisition Neutral NLS Pharmaceutics Positive SummaryJATT Acquisition beats NLS Pharmaceutics on 4 of the 7 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.03M$2.56B$5.75B$9.81BDividend YieldN/A1.76%3.91%4.13%P/E RatioN/A22.4731.1125.06Price / SalesN/A557.83432.4199.03Price / CashN/A170.4436.7858.67Price / Book-6.785.079.086.18Net Income-$1.98M$31.61M$3.26B$265.11M7 Day Performance17.29%25.12%7.38%4.22%1 Month Performance11.56%2.78%4.21%0.77%1 Year Performance1,305.38%10.98%30.29%24.68% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$2.51-3.8%N/A+1,305.4%$9.03MN/A0.006News CoverageShort Interest ↓Gap UpJATTJATT AcquisitionN/A$1.50+7.1%N/A-49.4%$25.88MN/A0.003High Trading VolumeMIRAMIRA Pharmaceuticals3.2451 of 5 stars$1.53-2.7%$17.00+1,012.6%-22.3%$25.80MN/A-2.992Earnings ReportShort Interest ↓BDRXBiodexa Pharmaceuticals1.0083 of 5 stars$7.05+1.0%N/AN/A$25.73M$470K0.0020Short Interest ↓NNVCNanoViricides0.3104 of 5 stars$1.60+0.3%N/A-30.4%$25.64MN/A-2.2220TENXTenax Therapeutics1.932 of 5 stars$6.05-2.0%$17.50+189.1%+42.5%$25.03MN/A-2.439News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionQTTBQ32 Bio2.6169 of 5 stars$1.95+0.8%$12.17+525.2%-94.7%$23.97M$1.16M-0.4039News CoverageShort Interest ↓CASICASI Pharmaceuticals4.0809 of 5 stars$1.94-0.4%$4.00+106.0%-63.7%$23.92M$31.37M-0.76180RLYBRallybio2.9827 of 5 stars$0.57+7.9%$10.00+1,651.3%-45.1%$23.76M$848K-0.5240Short Interest ↓LGVNLongeveron3.6784 of 5 stars$1.57-8.2%$8.67+452.0%-67.7%$23.44M$2.39M-0.2520News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpAYTUAytu BioPharma3.7718 of 5 stars$2.57-3.0%$10.00+289.0%-16.3%$23.30M$81M-3.60160News Coverage Related Companies and Tools Related Companies JATT Acquisition Alternatives MIRA Pharmaceuticals Alternatives Biodexa Pharmaceuticals Alternatives NanoViricides Alternatives Tenax Therapeutics Alternatives Q32 Bio Alternatives CASI Pharmaceuticals Alternatives Rallybio Alternatives Longeveron Alternatives Aytu BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access